Charles River Laboratories has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium and will provide the organization with access to its resources and services.
The global contract research organization (CRO) is increasing its focus on hepatotoxicity, one of the leading causes of adverse events in clinical trials.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.
Crown Bioscience has expanded its San Diego facility to create its US Center of Excellence for Oncology in order to support increasing demand for oncology research studies.
The EMA is recommending the suspension of several medicines after inspections revealed flawed studies at the India-based contract research organization (CRO), Semler Research Centre.
CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.
Researchers supported by the National Institutes of Health (NIH) have developed a clinical-grade stem cell line, which will help accelerate early-stage clinical research.
As a dedicated Chemical Biology Consortium center, AMRI will provide a variety of drug discovery services to help advance early stage drug discovery projects.
WuXi AppTec has adopted Elsevier’s technology as the company begins to focus less on point solutions, and more on provider partnerships, says VP of procurement.
Sensors, computer vision, machine learning, and cloud computing are enabling preclinical researchers to conduct higher quality studies in a shorter period of time.
Rising drug prices and the subsequent increasing number of drugs ineligible for reimbursement will challenge drug developers to provide clinical superiority evidence.
Charles River Laboratories is conducting new studies using animal models to give insight into therapeutic strategies where pharma companies expect to see the most success.
More drug discovery work will be outsourced this year according to a report which suggests pharmaceutical industry desire to reduce the risk of failure and cut costs persists.
Researchers have developed an organ-on-a-chip model that will allow for preclinical testing in an environment analogous to the human gastrointestinal tract.
Mass Innovation Labs is working to change the way biopharmaceutical companies conduct research by providing a “crossroads” for CRO service providers, vendors, and investors.
As a significant amount of drug discoveries occur outside of pharma companies, Elsevier has launched The Hive Project to promote innovation in the market – outside its walls.
While there are currently several techniques for producing tissue from heart cells, a new method reduces the amount of cells needed, making it easier and cheaper to replicate.
Replikins’ genomic understanding of the Zika and Flaviviruses has led to the development of a trivalent vaccine for Zika, Dengue, and Japanese Encephalitis.
Finding the right patients quickly is an ongoing problem in launching clinical trials, so several companies have formed an alliance to advance precision medicine development.
Microbial expression systems are cheaper and more efficient than mammalian cell cultures says BioSilta which has acquired the rights to an E. coli based platform.
Crown Bioscience has developed humanized mouse cancer models which it claims provide biologic drug developers with an improved means of assessing efficacy.
Propanc Health Group Corporation has received $1.2m from an institutional investor in order to fast track preclinical activities for its lead product, PRP.
Metrion Biosciences has been awarded a grant to develop CiPA-compliant stem cells and screening technologies by Eurostars, a European Union (EU) programme.
